Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Buy" from Brokerages

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has earned an average recommendation of "Buy" from the ten analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $28.38.

RCUS has been the subject of a number of recent research reports. Morgan Stanley decreased their price objective on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their price target for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Barclays dropped their price objective on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. Finally, Bank of America reduced their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th.

Arcus Biosciences Stock Up 5.8 %

Shares of NYSE RCUS opened at $9.12 on Friday. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $18.98. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The company's 50 day moving average price is $8.58 and its 200-day moving average price is $12.71. The company has a market capitalization of $958.86 million, a P/E ratio of -2.90 and a beta of 1.54.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.14. The company had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Equities analysts forecast that Arcus Biosciences will post -3.15 earnings per share for the current year.

Insider Activity at Arcus Biosciences

In other news, Director Yasunori Kaneko acquired 20,000 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, February 27th. The stock was bought at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the transaction, the director now owns 28,400 shares in the company, valued at $285,704. The trade was a 238.10 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Terry J. Rosen acquired 19,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the purchase, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arcus Biosciences

Large investors have recently made changes to their positions in the business. Gilead Sciences Inc. bought a new stake in Arcus Biosciences in the 4th quarter valued at $447,610,000. Barclays PLC increased its holdings in shares of Arcus Biosciences by 49.0% in the third quarter. Barclays PLC now owns 118,693 shares of the company's stock worth $1,816,000 after purchasing an additional 39,015 shares during the last quarter. Norges Bank purchased a new stake in shares of Arcus Biosciences in the fourth quarter worth about $507,000. US Bancorp DE lifted its position in shares of Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company's stock worth $103,000 after buying an additional 6,615 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Arcus Biosciences during the fourth quarter valued at approximately $207,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.